ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. Previously, all of its marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. By adding a new drug delivery solution, ALK-Abelló saw a marked improvement in patient tolerability, preference, and compliance.
Very few new molecular entities in active clinical development are readily bioavailable, and, when dosed at escalated levels, even these may not be sufficiently absorbed. Learn how spray-dried amorphous dispersion might help.
Arguably the biggest challenge in pediatric oral solid formulation development is to develop flexible dosage forms with measurable and easy to administer dosage, preferably formulated with taste-masking properties for better acceptance of the drug formulation in children. This Q&A session with formulation and bioavailability experts addresses formulation challenges for pediatric populations and how they are overcoming them.
Explore how a fast-dissolve technology can provide dosing solutions for various patient population groups. Whether you are considering an ODT to enhance pharmacokinetics through pre-gastric absorption, looking for a way to improve patient compliance, or seeking a marketing advantage for a valued brand, this technology solution can help enhance the value of your investment and accelerate a product’s potential.